Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2022 16:30 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
January 31, 2022 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
December 13, 2021 17:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Announces Strategic Reprioritization

- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – - Workforce reduction of approximately 38% – - Anticipated cash runway extended into 2024 – ...
November 29, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
November 10, 2021 16:15 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1...
November 09, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
September 09, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
September 02, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
August 10, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

CAMBRIDGE, Ma., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
July 23, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases

CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...